"In patients with metastatic castration-resistant prostate cancer, researchers have found that androgen receptor pathway inhibitors (ARPIs) outperformed the standard of care, which improved responses to treatment and overall survival (OS; time a patient lives, regardless of disease status)."
We are talking about sequential therapy in this case, triplet is a different story (and it's used in castration sensitive setting).
„ARPIs May Improve Survival in Some With Prostate Cancer“ - that is why they got an FDA approval! The editor of this article in cure magazine has misunderstood the press release.
It refers to the ProBio trial news-release: eurekalert.org/news-release... The ProBio trial has been published in nature: nature.com/articles/s41591-...
The trial did DNA tests to determine biomarker signatures to decide if the CRPC patient should be treated with chemo or ARPIs. There was a control arm called physician's choice which meant the therapy the physician would typically recommend for his patient. The trial was done to determine if a biomarker–treatment combination is superior compared to a physician’s choice of treatment within that biomarker or patient group.
If the patients got one of these therapies based on the biomarker signatures, ARPIs demonstrated a longer overall survival of 38.7 months compared to 21.7 months for chemo and 21.8 months for the physician’s choice control group.
The trial was presented at ESMO 2023: urotoday.com/conference-hig... There is also an interview with Dr. Grönberg urotoday.com/video-lectures...
Here is the ProBio trial on X: x.com/ProBioTrial
Bipolar Androgen Therapy in Prostate Cancer.Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs?
Survival rates for prostate cancer with bone metastases
The Survival Rate of Metastatic and Advanced Prostate Cancer
Long term AR signaling‐targeted therapy with taxane sometimes associated with visceral metastasis in castration‐resistant prostate cancer
